Stable gene transfer into hepatocytes might be used to compensate for a genetic deficiency affecting liver function or to deliver diffusible factors into the blood stream. In rats, we have combined retroviral-mediated gene transfer with a surgical procedure in which the liver is temporarily excluded from the circulation and infected in vivo. Partial hepatectomy was performed 24-48 hr before perfusion with virus to induce hepatocyte division and facilitate viral integration. A helper-free recombinant retrovirus coding for P-galactosidase with nuclear localization was used to score cells that expressed the transgene. For at least 3 months after gene transfer, up to 5% of hepatocytes expressed nuclear 3-galactosidase. Whereas in vitro reimplantation of genetically modified hepatocytes has proved to be inefficient in stably transferring genes into the liver, our approach provides a feasible alternative.
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A meethod for safe, efficient, and stable introduction of foreign DNA into hepatocytes would allow the development of protocols for the genetic treatment of many inborn errors of the metabolism.
Replication-defective retroviral vectors ensure genomic integration of a few transgene copies in an unrearranged and permanent configuration transmitted to the cell progeny. The stability and long-term expression of transgenes introduced by retroviral vectors in vivo has been documented in a variety of somatic tissues (1) (2) (3) (4) . Use of helper-free packaging cell lines (5) has shown that the replication-defective recombinant retrovirus is not transmitted to nontargeted organs (4, 6) and a fortiori to other organisms.
Freshly explanted hepatocytes are susceptible to retrovirus infection (7) , and strategies for gene transfer into the liver involving in vitro infection of cultured liver cells followed by reimplantation have been proposed. However, whereas fresh hepatocytes can be efficiently engrafted into the spleen (8, 9) or the liver (10) , most in vitro cultured and infected cells lose their capacity to be transplanted back (11) . Therefore, the feasibility of large-scale gene transfer to the liver by this approach is unlikely. Our purpose was to develop an alternative method whereby the hepatocytes would directly receive the transgene in situ. Because cell division is required for genomic integration of retroviruses and because most hepatocytes are quiescent cells in the adult liver, retroviral infection of the steady-state organ is expected to be inefficient. On the other hand, partial resection of the liver is followed by a regenerative phase that rapidly reconstitutes a full-size organ. Many hepatocytes enter the cell cycle during this process (12, 13) and should be susceptible to retrovirus infection at this time. After complete restoration of the organ weight, hepatocytes return to a quiescent state (12, 13) , and prolonged persistence of infected cells may be expected. Therefore, the in situ infection of hepatocytes with recombinant retroviral vectors may be a suitable method for long-term complementation of a genetic defect.
To target in vivo retrovirus infection to the liver, we surgically excluded the remnant liver lobes of partially hepatectomized rats from the circulation. A 10-min asanguineous perfusion of the regenerating tissue was then performed with a solution containing purely defective retrovirus vectors. After blood circulation was reestablished, liver regeneration proceeded until completion. A nuclear 3-galactosidase reporter gene (14) encoded by the vector allowed the detection of infected cells in animals sacrificed 2-14 weeks after the perfusion. The expression of the recombinant provirus was observed in up to 5% of the hepatocytes, whereas in other tissues, including spleen, lung, kidney, and brain, no recombinant provirus could be detected in cellular DNA by using the polymerase chain reaction (PCR).
MATERIALS AND METHODS
Amphotropic Retroviral Vector and Virus Assays. The pMFG retroviral vector was obtained from B. C. Guild, P. Robbins, L. Cohen, and R. C. Mulligan (Whitehead Institute, Cambridge, MA). A 3.5-kilobase pair (kbp) DNA fragment containing a modified lacZ gene (nls-lacZ), which codes for the Escherichia coli 13-galactosidase fused to a 21-amino acid nuclear-localization sequence from simian virus 40 large tumor antigen (14) , was introduced at the BamHI site. The nls-lacZ gene was transcribed from the long terminal repeat (LTR), and the mRNA was spliced by using the viral donor and acceptor sites. Sequences in the Moloney murine leukemia virus gag gene (up to position 1035) have been retained to increase the packaging efficiency of the unspliced transcript. The pMFG-NB construct was transfected into the ICRE ecotropic packaging cell line (5) by calcium phosphate-DNA coprecipitation. Forty-eight hours later, the culture medium was harvested and used to infect an amphotropic packaging cell line, ICRIP (5) . Individual ICRIP clones expressing the nls-lacZgene were isolated after fluorescenceactivated cell sorting of the infected population with fluorescein di-3-D-galactopyranoside as described (15) . Titers of nls-lacZ-transducing retroviruses were determined by infecting mouse NIH 3T3 fibroblasts with serial dilutions of the culture medium from each clone. Forty-eight hours later, the cells were incubated with 5-bromo-4-chloro-3-indolyl /3-Dgalactopyranoside (X-Gal; Sigma) substrate at 320C for 8 hr to reveal nuclear P-galactosidase activity (16) , and cell clusters with blue nuclei were counted. Filtered supernatant from the NB5 clone used in this study contained 5 x 1 f8-galactosidase focus-forming units (ffu) per ml. The absence of contamination with replication-competent retrovirus was controlled in the MFG-NB retrovirus vector stocks, in animal sera, and in liver and spleen extracts by an amplification and mobilization assay whose sensitivity is <1 ffu of ecotropic or Abbreviations: LTR, long terminal repeat; X-Gal, 5-bromo-4chloro-3-indolyl P-D-galactoside; nls, nuclear localization sequence; ffu, focus-forming units. tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. amphotropic helper virus per ml. This assay is based on the rescue of a defective retroviral genome containing lacZ and neo genes (17 (8, 9) and after migration into the liver (10). We injected either freshly isolated or in vitro infected and nls-lacZ-marked hepatocytes into the spleens of syngeneic rats. Two weeks later, the animals were sacrificed, and their spleens were examined by histological sections. Whereas splenic liver cell foci were routinely observed after transplantation of freshly explanted cells, none could be obtained when liver cells had been previously cultivated, even when hepatectomy was performed at the time of implantation (data not shown).
In Situ Infection ofHepatocytes with Retrovirus Vector in the Regenerating Liver. We reasoned that a partial hepatectomy followed by the direct injection of a defective retrovirus vector into the remnant liver lobes might bypass the difficulty of reimplanting in vitro infected hepatocytes. To prevent rapid dissemination of viral particles in the blood stream and destruction of retrovirus particles by serum complement, we surgically isolated the regenerating liver from the circulation (Fig. 1) (Fig. 2 A and B) . In all animals, the presence of f-galactosidase-positive cells was detected on X-Galstained cryostat sections (Fig. 2C) . Table 1 shows the num- bers of positive cells scored on sections chosen randomly from the hepatic parenchyma of experimental animals. The fraction of infected cells in the whole organ was estimated to be 1-5% x 106 cells) in rats 4-10, which had been perfused 24 hr after partial hepatectomy. In contrast, <0.05% of the cells were found to be infected in rats 1, 2, and 3, which were perfused 48 hr after partial hepatectomy. The number of infected cells in rat 10, which was sacrificed 14 weeks after treatment, was as high as in rats 4, 5, 7, and 6 sacrificed respectively 3, 3, 2, and 6 weeks after the perfusion. p-Galactosidase-positive cells appeared in small clusters (Table 1) and were observed scattered throughout the hepatic parenchyma ( Fig. 2A) . These clusters contained an average number of 1.7 cells, suggesting that most of the cells underwent only one division after the integration of the retrovirus vector genome. No positive cells were observed in either portal or terminal hepatic vascular walls. Cells expressing the transgene had a characteristically large and frequently double nucleus and were localized in the hepatic columns (Fig. 2C) . f3-Galactosidase-positive liver sections were counterstained with a monoclonal antibody recognizing a specific antigen on the sinusoidal plasma membrane (Fig. 2D) (20) or with an antiserum directed against rat albumin (Fig. 2E) . Immunostaining detection of rat albumin was positive in 91% of liver cells in animals 1 and 4. Cells expressing P-galactosidase in their nuclei were also found to be positive for albumin immunostaining in their cytoplasm (41 of 41 examined cells in rat 1 and 31 of 33 in rat 4). These data showed that P-galactosidase-positive cells were differentiated hepatocytes.
Since the regenerating liver was isolated from the blood flow during perfusion of defective retrovirus vector, we expected that the infection would be restricted to this organ. To ensure that no virus had spread out to other organs, we used the PCR to look for the presence of provirus copies in high molecular weight DNAs prepared from lung, spleen, kidney, and brain as well as from liver (see Materials and Methods). Fig. 3 shows that the vector sequences were present in liver cell DNA but absent in DNAs prepared from other tissues. This indicated that the perfusion procedure described here did not result in any significant leak of recombinant retrovirus to other organs.
It also suggested that replication-competent helper virus was absent from the stocks used for perfusion and did not appear in the animals as a consequence of the treatment. This latter point was confirmed by using a highly sensitive virus mobilization assay (17) that detected no replicating virus particles in the sera, spleen extracts, and liver extracts of treated animals (data not shown). DISCUSSION We show in this paper that retroviral vectors can be used to introduce foreign genes into hepatocytes of the regenerating liver without infecting other tissues. This was obtained by performing a two-thirds hepatectomy followed 24 or 48 hr later by a perfusion of the remnant liver lobes with a helper-free retrovirus vector preparation.
Cells expressing the -3-galactosidase transgene were identified in small, scattered clusters. This suggested that most of those cycling hepatocytes that integrated the vector underwent less than two subsequent cell divisions. Because the duration ofthe adult rat hepatocyte cell cycle is 33 hr (13) and the regeneration process generally proceeds for about 7 days (12, 22) , our observation supports the notion that most hepatocytes participate in regeneration. The numbers of infected hepatocytes were higher when the virus perfusions were performed during the peak of DNA synthesis at 24 hr. At this time, the fraction of cells undergoing DNA synthesis is estimated to be 15% (12) , and 30%o of the hepatocytes enter the cell cycle during the next 12 hr (13) ing the effects of more concentrated virus stocks, increased perfusion times, and addition of hepatocyte growth factors (23, 24) to the perfusion medium.
Most gene-transfer protocols to somatic tissues using retrovirus vectors involve the explantation of target cells, followed by their in vitro infection and reimplantation into the organism. In agreement with recently published work (11), we have observed that cultured hepatocytes rapidly lose most of their in vivo repopulating capacities, negating the possibility of using them for large-scale organ reconstitution. We show here that the in situ approach provides an alternative for gene transfer into the hepatocytes. In situ gene transfer to the liver was previously reported using direct injection (25) or bombardment (26) of DNA plasmids into the organ, injection of vesicle complexes (27) or retroviruses (28) into the portal vein, or injection of DNA complexed with asialoglycoproteins in the blood stream (29, 30) . However, none of these reports documented the nature of the cells in which foreign DNA was expressed. Indeed the liver tissue associates many different cell types including phagocytic cells, and most ofthe liver metabolic and secretory functions are provided by hepatocytes only. Those latter cells should be the preferential target for a therapeutic gene transfer when the restoration of normal functions to a genetically deficient liver or the replacement of a missing diffusible factor is desired. The hepatocyte mitotic index in the steady-state liver is 0. 1-0.5% (31, 32) . This low turnover suggests that direct in situ gene transfer into hepatocytes might be compatible with long-term complementation of genetic deficiencies.
The procedure that we describe here could be technically adapted to human patients. Indeed, human hepatocytes are sensitive to infection with amphotropic murine retroviruses (our unpublished observations), and selective perfusion of liver lobes as well as partial hepatectomy are surgical procedures currently carried out in human patients undergoing treatment for liver tumors (33) .
